Literature DB >> 69217

15-keto-13,14-dihydroprostaglandin E2 concentrations in serum of patients with breast cancer.

T J Powles, R C Coombes, A M Neville, H T Ford, J C Gazet, L Levine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 69217     DOI： 10.1016/s0140-6736(77)90146-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.

Authors:  S Nigam; A Zakrzewicz; S Eskafi; A Roscher
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 2.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

3.  The levels and relations of prostaglandins in pregnant and non-pregnant tumor-bearing mice.

Authors:  H Mujagić; N Krnjajić; A Jevrić
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients.

Authors:  T Malachi; C Chaimoff; N Feller; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

5.  Prostaglandin E2 and cyclic nucleotides in plasma and urine of colonic cancer patients.

Authors:  C Chaimoff; T Malachi; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  Immune regulation of the L5178Y murine tumor-dormant state. I. In vivo and in vitro effects of prostaglandin E2 and indomethacin on tumor cell growth.

Authors:  C M Liu; T Okayasu; P Goldman; Y Suzuki; K Suzuki; E F Wheelock
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

7.  Prostaglandin F2 alpha in benign and malignant breast tumours.

Authors:  I B Vergote; G M Laekeman; G H Keersmaekers; F L Uyttenbroeck; J S Vanderheyden; G P Albertyn; C F Haensch; G J De Roy; A G Herman
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

8.  Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours.

Authors:  M Alam; M Jogee; W G MacGregor; J W Dowdell; M G Elder; L Myatt
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.